A4POE*4-associated Alzheimer’s disease risk is modified by α1–antichymotrypsin polymorphism

Nature Genetics

Volumn 10, Issue 4, 1995, Pages 486-488

  Kamboh, M Ilyas ^a   Sanghera, Dharambir K ^a   Ferrell, Robert E ^a   DeKosky, Steven T ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; APOLIPOPROTEIN E; PRIMER DNA; AMYLOID BETA PROTEIN; CHYMOTRYPSIN A;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; MALE; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; RISK FACTOR; CONTROLLED STUDY; GENE DOSAGE; GENETIC SUSCEPTIBILITY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ALPHA 1-ANTICHYMOTRYPSIN; ALZHEIMER DISEASE; APOLIPOPROTEINS E; BASE SEQUENCE; DNA PRIMERS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMAN; MALE; MIDDLE AGE; MOLECULAR SEQUENCE DATA; POLYMORPHISM (GENETICS); RISK FACTORS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0028990941     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng0895-486     Document Type: Article

References (26)

1. Strittmatter, W. J. et al. Apolipoprotein E: high avidity binding to-amyloid and increased frequency of type 4 allele in late-onset familial Alzheirner disease. Proc. natn. Acad. Sci. U. S. A. 90, 1977-1981 (1993).
2. Saunders, A. M. et al. Association of apolipoprotein E allele 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology 43, 1467-1472 (1993).
3. Kamboh, M. I. Apolipoprotein E polymorphism and susceptibility to Alzheimer’s disease. Hum. Biol. 67, 195-215 (1995).
4. Abraham, C. R., Selkoe, D. J. & Potter, H. Immunochemical identification of the serine protease inhibitor 1-antichymotrypsin in the brain amyloid deposits of Alzheimer’s disease. Cell 52, 487-501 (1988).
5. Abraham, C. R., Shirahama, T. & Potter, H. 1-antichymotrypsin is associated solely with amyloid deposits containing the-protein: amyloid and cell localization of 1-antichymotrypsin. Neurobiol. Aging 11, 123-129 (1990).
6. Picken, M. M. et al. Distribution of the protease inhibitor 1-antichymotrypsin in cerebral and systemic amyloid. J. Neuropathol. exp. Neurol. 49, 41-48 (1990).
7. Rozemuller, J. M. et al. Distribution pattern and functional state of 1-antichymotrypsin in plaques and vascular amyloid in Alzheimer’s disease. Acta Neuropath. 82, 200-207 (1991).
8. Shoji, M. et al. Alpha 1-antichymotrypsin is present in diffuse senile plaques: a comparative study of-protein and 1-antichymotrypsin immunostaining in the Alzheimer brain. Am. J. Path. 138, 247-257. (1991).
9. Fraser, P. E., Nguyen, J. T., McLachlan, D. R., Abraham, C. R. & Kirschner, D. A. 1-antichymotrypsin binding to Alzheimer A peptides is sequence specific and induces fibril disaggregation in vitro. J. Neurochem. 61, 298-305 (1993).
10. Ma, J., Yee, A., Brewer, H. B. Jr., Das, S. & Potter, H. Amyloid-associated proteins 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer-protein into filaments. Nature 372, 92-94 (1994).
11. Ishiguro, K. et al. Differential expression of 1-antichymotrypsin in the aged human brain. Virchows Arch. B. Cell Path. 64, 221-227 (1993).
12. Wisniewski, K. E. & Kida, E. Proteinase inhibitor 1-antichymotrypsin has different expression in various forms of neuronal ceroid lipfuscinosis. Exp. Neurol. 110, 121-126 (1990).
13. Faber, J.-P. et al. The molecular basis of 1-antichymotrypsin deficiency in a heterozygote with liver and lung disease. J. Hepatol. 18, 313-321 (1993).
14. Strittmatter, W. J. et al. Hypothesis-microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. Expl. Neurol. 125, 163-171 (1994).
15. Randall, L. L. & Hardy, S. J. S. Unity in function in the absence of consequence in sequence: role of leader peptides in export. Science 243, 1156-1159 (1989).
16. Matsubara, E. et al. Alpha 1-antichymotrypsin as a possible biochemical marker for Alzheimer-type dementia. Ann. Neurol. 28, 561-567 (1990).
17. Rayford, A., Rao, J. S. & Festoff, B. W. Characterization of the serpin, 1-antichymotrypsin, in normal human cerebrospinal fluid. J. Neurochem. 58, 88-94 (1992).
18. Wisniewski, T., Castano, E. M., Golabek, A., Vogel, T. & Frangione, B. Acceleration of Alzheimer’s fibril formation by apolipoprotein E in vitro. Am. J. Pathol. 145, 1030-1035 (1994).
19. Sanan, D. A. et al. Apolipoprotein E associates with A amyloid peptide to form novel monofibrils: Isoform apoE4 associates more efficiently than apoES. J. Clin Invest. 94, 880-889 (1994).
20. DeKosky, S. T. et al. Alzheimer’s disease and related dementias: report of follow-up on the first 1, 000 cases from Pittsburgh. Neurology 44, A354-355 (1994).
21. McKhann, G. et al. Clinical diagnosis of Alzheimer’s disease. Neurology 34, 939-944 (1984).
22. Diagnostic and Statistical Manual of Mental Disorders: DSM-III-R. (3rd revised edn) (Washington, D. C. American Psychiatric Association, (1987).
23. Khachaturian, Z. Diagnosis of Alzheimer’s disease. Arch. Neurol. 42, 1097-1105 (1985).
24. Mirra, S. S. et al. The consortium to establish a registry for Alzheimer’s disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 41, 479-486 (1991).
25. Kamboh, M. I., Aston, C. E. & Hamman, R. F. The relationship of APOE polymorphism and cholesterol levels in normoglycemic and diabetic subjects in a biethnic population from the San Luis Valley, Colorado. Atherosclerosis 112, 145-159 (1995).
26. Eichner, J. E., Kuller, L. H., Ferrell, R. E., Meilahn, E. N. & Kamboh, M. I. Phenotypic effects of apolipoproteins structural variation on lipid profiles. III. The contribution of APOE to prediction of total cholesterol, apoB and LDL-C in the Healthy Women Study. Arteriosclerosis 10, 379-385 (1990).